KR20090023643A - 당뇨병 치료를 위한 sglt2 억제제로서의, (1s)-1,5-안히드로-1-c-(3-((페닐)메틸)페닐)-d-글루시톨 유도체와 아미노산의 결정질 용매화물 및 복합체 - Google Patents
당뇨병 치료를 위한 sglt2 억제제로서의, (1s)-1,5-안히드로-1-c-(3-((페닐)메틸)페닐)-d-글루시톨 유도체와 아미노산의 결정질 용매화물 및 복합체 Download PDFInfo
- Publication number
- KR20090023643A KR20090023643A KR1020087031643A KR20087031643A KR20090023643A KR 20090023643 A KR20090023643 A KR 20090023643A KR 1020087031643 A KR1020087031643 A KR 1020087031643A KR 20087031643 A KR20087031643 A KR 20087031643A KR 20090023643 A KR20090023643 A KR 20090023643A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- crystalline
- formula
- proline
- solvate
- Prior art date
Links
- JVHXJTBJCFBINQ-ADAARDCZSA-N CCOc1ccc(Cc2cc([C@@H]([C@@H]([C@H]3O)O)O[C@H](CO)[C@H]3O)ccc2Cl)cc1 Chemical compound CCOc1ccc(Cc2cc([C@@H]([C@@H]([C@H]3O)O)O[C@H](CO)[C@H]3O)ccc2Cl)cc1 JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 4
- 0 *C=CC(Cc1ccccc1)=CC=C Chemical compound *C=CC(Cc1ccccc1)=CC=C 0.000 description 2
- PCNBUBPRQUQMDV-YRNVUSSQSA-N C/C(/Cc1ccccc1)=C\C=C Chemical compound C/C(/Cc1ccccc1)=C\C=C PCNBUBPRQUQMDV-YRNVUSSQSA-N 0.000 description 1
- XPNJNHGFUZJXNP-ZEBDFXRSSA-N CC(C)[C@@H]([C@@H]([C@H]1O)O)O[C@H](CO)[C@H]1O Chemical compound CC(C)[C@@H]([C@@H]([C@H]1O)O)O[C@H](CO)[C@H]1O XPNJNHGFUZJXNP-ZEBDFXRSSA-N 0.000 description 1
- UMKANPFRVKUHEC-PLGYGGSJSA-N CCOc1ccc(Cc2cc([C@]([C@@H]([C@H]3C)O)(OC)O[C@H](CO)[C@H]3O)ccc2Cl)cc1 Chemical compound CCOc1ccc(Cc2cc([C@]([C@@H]([C@H]3C)O)(OC)O[C@H](CO)[C@H]3O)ccc2Cl)cc1 UMKANPFRVKUHEC-PLGYGGSJSA-N 0.000 description 1
- GKTWLVVOULBRDU-BDHVOXNPSA-N CCOc1ccc(Cc2cc([C@]([C@@H]([C@H]3O)O)(OC)O[C@H](CO)[C@H]3O)ccc2Cl)cc1 Chemical compound CCOc1ccc(Cc2cc([C@]([C@@H]([C@H]3O)O)(OC)O[C@H](CO)[C@H]3O)ccc2Cl)cc1 GKTWLVVOULBRDU-BDHVOXNPSA-N 0.000 description 1
- FFZCILQFUMSYHP-XXFSISAASA-N CC[C@@H]([C@@H]([C@H]1OC)OC)O[C@H](C)[C@H]1OC Chemical compound CC[C@@H]([C@@H]([C@H]1OC)OC)O[C@H](C)[C@H]1OC FFZCILQFUMSYHP-XXFSISAASA-N 0.000 description 1
- WALBOXSPQGJMIT-NQNKTMCVSA-N CC[O](C)(C)c1ccc(Cc2cc([C@@H]([C@@H]([C@H]3O)O)OC(CO)[C@H]3O)ccc2Cl)cc1 Chemical compound CC[O](C)(C)c1ccc(Cc2cc([C@@H]([C@@H]([C@H]3O)O)OC(CO)[C@H]3O)ccc2Cl)cc1 WALBOXSPQGJMIT-NQNKTMCVSA-N 0.000 description 1
- JLWZOFXAKVSFCO-BYPYZUCNSA-N O=C([C@H]1NCCC1)N=O Chemical compound O=C([C@H]1NCCC1)N=O JLWZOFXAKVSFCO-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N OC([C@H]1NCCC1)=O Chemical compound OC([C@H]1NCCC1)=O ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (56)
- 제1항에 있어서, (S)-PG (형태 SC-3), (R)-PG (형태 SD-3), EtOH (형태 SA-1), 에틸렌 글리콜 (EG) 구조물 (형태 SB-1) 및 에틸렌 글리콜 (EG) 구조물 (형태 SB-2), 1:2 L-프롤린 구조물 (형태 3), 1:1 L-프롤린 구조물 (형태 6), 1:1 L-프롤린 반수화물 구조물 (형태 H.5-2), 및 1:1 L-페닐알라닌 구조물 (형태 2)로 구성된 군으로부터 선택된 구조물을 포함하는 결정질 구조물.
- 제2항에 있어서, 상기 구조물 각각이 실질적으로 순수한 형태인 결정질 구조물.
- 제5항에 있어서, 하기 사항 중 하나 이상을 특징으로 하는 결정질 구조물 (S)-PG (형태 SC-3):a) 이하와 실질적으로 동일한 단위 셀 파라미터:셀 치수:a = 11.2688(8) Åb = 4.8093(3) Åc = 46.723(3) Åα = 90°β = 90°γ = 90°스페이스기 = P212121분자/비대칭 단위 = 1(여기서, 상기 결정질 구조물의 측정은 실온에서 이루어지고,실질적으로 표 4에 나타낸 바와 같은 구획별 원자 좌표를 특징으로 함),b) 실온에서 3.8±0.1, 7.6±0.1, 8.1±0.1, 8.7±0.1, 15.2±0.1, 15.7.4±0.1, 17.1±0.1, 18.9±0.1 및 20.1±0.1로 구성된 군으로부터 선택된 2θ 값 (CuKα λ = 1.5418 Å)을 포함하는 분말 X-선 회절 패턴,c) 400 MHz 분광계로 측정할 때, 0에서의 TMS에 대하여 16.2, 17.6, 39.3, 60.9, 63.3, 69.8, 76.9, 78.7, 79.4, 113.8, 123.6, 129.3, 130.5, 132.0, 135.7, 139.1 및 158.0 ppm과 실질적으로 유사한 피크 위치를 갖는 고체 상태 13C NMR 스펙트럼,d) 약 50℃ 내지 78℃ 범위 내에서 흡열을 갖거나 또는 도 7에 나타낸 바와 같은 시차 주사 열량측정 열분석도,e) 실온 정도 내지 약 240℃ 이하에서 약 18.7% 중량 손실을 갖거나 또는 도 5에 나타낸 바와 같은 열중량 분석 곡선, 또는f) 표 1A에 나타낸 것과 실질적으로 유사한 피크 위치를 갖는 양성자 NMR.
- 제2항에 있어서, 하기 사항 중 하나 이상을 특징으로 하는 결정질 구조물 (R)-PG:a) 실온에서 3.9±0.1, 8.0±0.1, 8.7±0.1, 15.3±0.1, 15.6±0.1, 17.2±0.1, 19.2±0.1, 19.9±0.1 및 20.3±0.1로 구성된 군으로부터 선택된 2θ 값 (CuKα λ = 1.5418 Å)을 포함하는 분말 X-선 회절 패턴,b) 400 MHz 분광계로 측정할 때, 0에서의 TMS에 대하여 15.8, 17.6, 39.0, 60.9, 63.2, 67.4, 69.7, 77.3, 79.2, 79.8, 113.3, 123.6, 129.0, 130.4, 132.0, 135.6, 139.2 및 157.9 ppm과 실질적으로 유사한 피크 위치를 갖는 고체 상태 13C NMR 스펙트럼,c) 약 43℃ 내지 60℃ 범위 내에서 흡열을 갖거나 또는 도 8에 나타낸 바와 같은 시차 주사 열량측정 열분석도, 또는d) 실온 정도 내지 약 235℃ 이하에서 약 18.7% 중량 손실을 갖거나 또는 도 6에 나타낸 바와 같은 열중량 분석 곡선.
- 제2항에 있어서, 하기 사항과 실질적으로 동일한 하나 이상의 단위 셀 파라미터를 특징으로 하는 결정질 구조물 EtOH (형태 SA-1):셀 치수:a = 11.519(1) Åb = 4.799(1) Åc = 22.648(1) Åα = -°β = 94.58(1)°γ = -°스페이스기 = P21분자/비대칭 단위 = 1(여기서, 상기 결정질 구조물의 측정은 -50℃에서 이루어지고,실질적으로 표 6에 나타낸 바와 같은 구획별 원자 좌표를 특징으로 함).
- 제2항에 있어서, 하기 사항과 실질적으로 동일한 하나 이상의 단위 셀 파라미터를 특징으로 하는 결정질 구조물 EG (형태 SB-1):400 MHz 분광계로 측정할 때, 0에서의 TMS에 대하여 12.49, 59.16, 60.61, 60.69, 68.10, 72.51, 76.11, 78.51, 79.02, 112.09, 125.16, 126.47, 127.38, 128.61, 129.02, 129.73, 135.62, 137.48 및 154.70 ppm과 실질적으로 유사한 피크 위치를 갖는 고체 상태 13C NMR 스펙트럼,셀 치수:a = 11.593(8) Åb = 4.766(5) Åc = 22.78(3) Åα = -°β = 93.38(9)°γ = -°스페이스기 = P21분자/비대칭 단위 = 1(여기서, 상기 결정질 구조물의 측정은 -50℃에서 이루어지고,실질적으로 표 8에 나타낸 바와 같은 구획별 원자 좌표를 특징으로 함).
- 제2항에 있어서, 하기 사항과 실질적으로 동일한 하나 이상의 단위 셀 파라미터를 특징으로 하는 결정질 구조물 EG (SB-2):셀 치수:a = 11.4950(1) Åb = 4.7443(1) Åc = 44.4154(5) Åα = -°β = -°γ = -°스페이스기 = P212121분자/비대칭 단위 = 1(여기서, 상기 결정질 구조물의 측정은 실온에서 이루어지고,실질적으로 표 10에 나타낸 바와 같은 구획별 원자 좌표를 특징으로 함).
- 제2항에 있어서, 하기 사항 중 하나 이상을 특징으로 하는 1:2 L-프롤린 복합체 Ih 형태 3의 결정질 구조물:셀 치수 (-60℃에서):a = 10.311(1) Åb = 11.334(1) Åc = 27.497(1) Åα = 95.94°β = 99.22°γ = 90°스페이스기 = P1분자/비대칭 단위 = 4(표 15A에 나타낸 바와 같은 구획별 원자 좌표를 특징으로 함),a) 실온에서 3.3±0.1, 6.5±0.1, 8.6±0.1, 15.7±0.1, 16.4±0.1, 17.2±0.1, 18.9±0.1, 19.8±0.1 및 20.3±0.1로 구성된 군으로부터 선택된 2θ 값 (CuKα λ = 1.5418 Å)을 포함하는 분말 X-선 회절 패턴,b) 185℃에서 흡열을 갖거나 또는 도 19에 나타낸 바와 같은 시차 주사 열량측정 열분석도, 또는c) 150℃ 이하에서 무시할만한 중량 손실을 갖거나 또는 도 16에 나타낸 바와 같은 열중량 분석 곡선.
- 제2항에 있어서, 하기 사항 중 하나 이상을 특징으로 하는 1:1 L-프롤린 복합체 Ii 형태 6의 결정질 구조물:셀 치수 (-40℃에서):a = 11.441(1) Åb = 10.235(1) Åc = 45.358(1) Åα = 90°β = 90°γ = 90°스페이스기 = P212121분자/비대칭 단위 = 2(표 16A에 나타낸 바와 같은 구획별 원자 좌표를 특징으로 함),a) 실온에서 3.9±0.1, 9.5±0.1, 15.4±0.1, 15.7±0.1, 15.9±0.1, 17.5±0.1, 18.7±0.1, 19.7±0.1 및 20.3±0.1로 구성된 군으로부터 선택된 2θ 값 (CuKα λ = 1.5418 Å)을 포함하는 분말 X-선 회절 패턴,b) 약 167℃에서 흡열을 갖거나 또는 도 20에 나타낸 바와 같은 시차 주사 열량측정 열분석도, 또는c) 실온 정도 내지 150℃ 이하에서 무시할만한 중량 손실을 갖거나 또는 도 17에 나타낸 바와 같은 열중량 분석 곡선.
- 제2항에 있어서, 하기 사항 중 하나 이상을 특징으로 하는 1:1 L-프롤린 반수화물 복합체 Ij 형태 H.5-2의 결정질 구조물:셀 치수 (-40℃에서):a = 11.539(1) Åb = 10.199(1) Åc = 23.183(1) Åα = 103.96°β = 97.16°γ = 90.25°스페이스기 = P1분자/비대칭 단위 = 4(표 18에 나타낸 바와 같은 구획별 원자 좌표를 특징으로 함),a) 실온에서 3.9±0.1, 8.8±0.1, 15.5±0.1, 15.8±0.1, 16.5±0.1, 17.8±0.1, 19.4±0.1, 19.7±0.1 및 20.8±0.1로 구성된 군으로부터 선택된 2θ 값 (CuKα λ = 1.5418 Å)을 포함하는 분말 X-선 회절 패턴,b) 약 25℃ 내지 125℃에서 흡열을 갖거나 또는 도 21에 나타낸 바와 같은 시차 주사 열량측정 열분석도, 또는c) 실온 정도 내지 약 125℃ 이하에서 약 1.7% 중량 손실을 갖거나 또는 도 18에 나타낸 바와 같은 열중량 분석 곡선.
- 제2항에 있어서, 1:1 L-페닐알라닌 (L-Phe) 복합체 Ik 형태 2인 결정질 구조물.
- 유효량의 제1항의 화학식 I의 화합물의 결정 구조물 및 제약상 허용가능한 담체 또는 희석제를 포함하는 제약 조성물.
- 치료 유효량의 제5항의 (S)-PG 결정 구조물 및 제약상 허용가능한 담체 또는 희석제를 포함하는 제약 조성물.
- 제16항에 있어서, 상기 결정질 구조물이 실질적으로 순수한 형태인 제약 조성물.
- 유효량의 제4항의 결정 구조물, 및 당뇨병 치료제, 항-비만제, 항-고혈압 작용제, 항-아테롬성동맥경화증 작용제 및 지질 저하제로 구성된 군으로부터 선택된 1종 이상의 치료제를 포함하는 제약 조성물.
- 포유동물에게 치료 유효량의 제4항의 결정질 구조물을 투여하는 것을 포함하는, 포유동물에서 당뇨병, 당뇨 망막증, 당뇨 신경병증, 당뇨 신장병증, 창상 치유 지연, 인슐린 내성, 과혈당증, 과인슐린혈증, 지방산 또는 글리세롤의 혈중 수준 증가, 고지혈증, 이상지혈증, 비만, 과트리글리세리드혈증, 증후군 X, 당뇨 합병 증, 아테롬성동맥경화증 또는 고혈압을 치료하거나, 또는 고밀도 지단백질 수준을 증가시키는 방법.
- 제22항에 있어서, 상기 반응 혼합물에 (S)-PG 화합물 Ia의 시드를 첨가하여 결정질 화합물 Ia가 형성될 수 있도록 하는 것인 방법.
- 제26항에 있어서, 환원제가 알킬실릴 수소화물이고, 활성화기가 루이스산인 방법.
- 제26항에 있어서, 환원제가 트리에틸실란이고, 활성화기가 BF3OEt2 또는 BF3 ·2CH3OOH인 방법.
- 제29항에 있어서, 환원제가 알킬실릴 수소화물이고, 활성화기가 루이스산인 방법.
- 제29항에 있어서, 환원제가 트리에틸실란이고, 활성화기가 BF3OEt2 또는 BF3·2CH3OOH인 방법.
- 제33항에 있어서, 하기 사항과 실질적으로 동일한 하나 이상의 단위 셀 파라미터를 특징으로 하는 결정질 구조물:셀 치수:a = 21.576(7) Åb = 6.755(1) Åc = 18.335(5) Åα = -°β = 102.96(1)°γ = -°스페이스기 = C2분자/비대칭 단위 = 1(여기서, 상기 결정질 구조물의 측정은 25℃에서 이루어지고,실질적으로 표 12에 나타낸 바와 같은 구획별 원자 좌표를 특징으로 함), 또는셀 치수:a = 21.537(4) Åb = 6.7273(6) Åc = 18.267(3) Åα = -°β = 102.924(7)°γ = -°스페이스기 = C2분자/비대칭 단위 = 1(여기서, 상기 결정질 구조물의 측정은 -50℃에서 이루어짐), 또는표 2A에 나타낸 것과 실질적으로 유사한 피크 위치를 갖는 양성자 NMR.
- 하기 사항과 실질적으로 동일한 하나 이상의 단위 셀 파라미터를 특징으로 하는 디메탄올 용매화물 구조 Ig의 화합물의 결정 구조물:셀 치수:a = 20.948(3) Åb = 6.794(2) Åc = 18.333(2) Åα = -°β = 102.91(2)°γ = -°스페이스기 = C2분자/비대칭 단위 = 1(여기서, 상기 결정질 구조물의 측정은 -50℃에서 이루어지고,실질적으로 표 14에 나타낸 바와 같은 구획별 원자 좌표를 특징으로 함), 또는표 2B에 나타낸 것과 실질적으로 유사한 피크 위치를 갖는 양성자 NMR.
- (S)-프로필렌 글리콜 용매화물 또는 (R)-프로필렌 글리콜 용매화물 또는 이들의 혼합물인, 하기 화학식 II의 화합물의 결정질 구조물:<화학식 II>상기 식에서,R1, R2 및 R2a는 독립적으로 수소, OH, OR5, 알킬, -OCHF2, -OCF3, -SR5a 또는 할로겐이고,R3 및 R4는 독립적으로 수소, OH, 0R5b, 알킬, 알켄, 알킨, 시클로알킬, CF3, -OCHF2, -OCF3, 할로겐, -CONR6R6a, -CO2R5c, -CO2H, -C0R6b, -CH(0H)R6c, -CH(OR5d)R6d, -CN, -NHC0R5e, -NHSO2R5f, -NHSO2아릴, -SR5g, -SOR5h, -SO2R5i, -SO2아릴이거나, 또는 고리 중에 N, O, S, SO 및/또는 SO2인 1개 또는 4개의 헤테로원자를 함유할 수 있는 5원, 6원 또는 7원의 헤테로사이클이거나, 또는R3 및 R4가 이들이 부착된 탄소와 함께 고리 중에 N, O, S, SO 및/또는 SO2인 1개 내지 4개의 헤테로원자를 함유할 수 있는 5원, 6원 또는 7원의 고리화 카르보사이클 또는 헤테로사이클을 형성하고,R5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h 및 R5i는 독립적으로 알킬, 알켄 또는 알킨이며,R6, R6a, R6b, R6c 및 R5d는 독립적으로 수소, 알킬, 아릴, 알킬아릴 또는 시클로알킬이거나, 또는R6 및 R6a가 이들이 부착된 질소와 함께 고리 중에 N, O, S, SO 및/또는 SO2인 1개 내지 4개의 헤테로원자를 함유할 수 있는 5원, 6원 또는 7원의 고리화 헤테로사이클을 형성한다.
- 제42항에 있어서, (S)-프로필렌 글리콜 용매화물인 결정질 구조물.
- 유기 용매 중 하기 화학식 C의 화합물을 염기 및 (S)-프로필렌 글리콜 또는 (R)-프로필렌 글리콜과 반응시키는 단계,임의로, (S)-PG 화합물 II 또는 상응하는 (R)-PG 화합물 III의 시드를 첨가하는 단계, 및하기 화학식 II의 시드를 사용하여 화학식 II의 (S)-PG 용매화물 화합물의 결정을 회수하는 단계, 또는 하기 화학식 III의 시드를 사용하여 화학식 III의 (R)-PG 용매화물의 결정을 회수하는 단계를 포함하는, 제42항에서 정의한 하기 화학식 II의 화합물 또는 그의 상응하는 (R)-PG 용매화물 (III)의 제조 방법:<화학식 II>
- 제46항에 있어서, 환원제가 알킬실릴 수소화물이고, 활성화기가 루이스산인 방법.
- 연속식 공정으로a) 리튬 시약을 사용하여 하기 구조의 방향족 반응물질 E를 비-극저온 온도에서 리튬화하여 하기 구조의 리튬화된 음이온 G를 형성하는 단계,b) 상기 리튬화된 음이온 종 G를 비-극저온 온도에서 하기 구조의 카르보닐 치환된 반응물질 D와 커플링하여 하기 구조의 글리코시드 H를 형성하는 단계,c) 상기 단계 b)에서 제조된 글리코시드 H를 산으로 처리하여 탈실릴화 헤미아세탈 H'를 형성하고, 이것을 하기 화합물 B로 전환시키는 단계, 및d) 상기 단계 c)의 화합물 B를 톨루엔/EtOAc 중 2-부틴-1,4-디올 J로 처리하여 화합물 If의 결정을 형성하는 단계를 포함하는, 비-극저온 공정을 이용한 하기 구조 If의 화합물의 제조 방법:
- 제52항에 있어서, 상기 리튬화 단계가 약 -30℃ 내지 약 20℃의 온도에서 수행되는 것인 방법.
- 제52항에 있어서, 상기 리튬화 단계가 약 -17℃ 내지 약 -10℃의 온도에서 수행되는 것인 방법.
- 제54항에 있어서, 상기 리튬 시약이 n-BuLi, s-BuLi 및 t-BuLi으로 구성된 군으로부터 선택된 것인 방법.
- 제52항에 있어서, 상기 커플링 단계가 약 -30℃ 내지 약 -10℃의 온도에서 수행되는 것인 방법.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81711806P | 2006-06-28 | 2006-06-28 | |
US60/817,118 | 2006-06-28 | ||
US11/765,481 US7919598B2 (en) | 2006-06-28 | 2007-06-20 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US11/765,481 | 2007-06-20 | ||
PCT/US2007/071749 WO2008002824A1 (en) | 2006-06-28 | 2007-06-21 | Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090023643A true KR20090023643A (ko) | 2009-03-05 |
KR101493102B1 KR101493102B1 (ko) | 2015-02-16 |
Family
ID=38581970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087031643A KR101493102B1 (ko) | 2006-06-28 | 2007-06-21 | 당뇨병 치료를 위한 sglt2 억제제로서의, (1s)-1,5-안히드로-1-c-(3-((페닐)메틸)페닐)-d-글루시톨 유도체와 아미노산의 결정질 용매화물 및 복합체 |
Country Status (33)
Country | Link |
---|---|
US (3) | US7919598B2 (ko) |
EP (4) | EP2069374B2 (ko) |
JP (6) | JP5313889B2 (ko) |
KR (1) | KR101493102B1 (ko) |
CN (2) | CN103145773B (ko) |
AR (1) | AR061730A1 (ko) |
AU (1) | AU2007265246B2 (ko) |
BR (3) | BR122017015106B8 (ko) |
CA (3) | CA2653344C (ko) |
CL (1) | CL2007001915A1 (ko) |
CO (1) | CO6160299A2 (ko) |
CY (1) | CY1115738T1 (ko) |
DK (1) | DK2069374T4 (ko) |
EA (4) | EA028259B1 (ko) |
ES (3) | ES2659862T3 (ko) |
HK (1) | HK1127359A1 (ko) |
HR (1) | HRP20141007T4 (ko) |
IL (5) | IL195882A (ko) |
MX (3) | MX367155B (ko) |
MY (2) | MY148566A (ko) |
NO (2) | NO346828B1 (ko) |
NZ (4) | NZ589195A (ko) |
PE (2) | PE20080349A1 (ko) |
PH (1) | PH12012500168A1 (ko) |
PL (1) | PL2069374T5 (ko) |
PT (1) | PT2069374E (ko) |
RS (1) | RS53638B2 (ko) |
SG (2) | SG172741A1 (ko) |
SI (1) | SI2069374T2 (ko) |
TW (4) | TWI466876B (ko) |
UA (1) | UA96765C2 (ko) |
WO (1) | WO2008002824A1 (ko) |
ZA (1) | ZA200810475B (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016018024A1 (ko) * | 2014-07-28 | 2016-02-04 | 한미정밀화학주식회사 | 다파글리프로진을 포함하는 결정질 복합체 및 이의 제조방법 |
WO2017099496A1 (ko) * | 2015-12-11 | 2017-06-15 | 동아에스티 주식회사 | 다파글리플로진의 신규 용매화물 및 이의 제조방법 |
WO2018097570A3 (ko) * | 2016-11-24 | 2018-08-09 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 |
KR20190038283A (ko) * | 2017-09-29 | 2019-04-08 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제 |
WO2019066359A3 (ko) * | 2017-09-29 | 2019-05-16 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제 |
Families Citing this family (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101119969B (zh) | 2004-07-15 | 2014-04-09 | 阿尔巴尼分子研究公司 | 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用 |
TW200726755A (en) * | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
CN101568537A (zh) * | 2006-12-21 | 2009-10-28 | 安斯泰来制药有限公司 | C-糖苷衍生物的制造方法及其合成中间体 |
TW200904405A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
TW200904454A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
CN101754972A (zh) * | 2007-05-18 | 2010-06-23 | 百时美施贵宝公司 | Sglt2抑制剂的晶体结构及其制备方法 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
CN104387354A (zh) * | 2007-12-27 | 2015-03-04 | 阿斯利康公司 | Sglt2 抑制剂的晶体结构及其制备方法 |
CN101468976B (zh) * | 2007-12-27 | 2013-11-20 | 百时美施贵宝公司 | Sglt2抑制剂的晶体结构及其制备方法 |
EP2236137B1 (en) | 2008-01-31 | 2015-06-24 | Astellas Pharma Inc. | Pharmaceutical composition for treatment of fatty liver diseases |
US8450286B2 (en) * | 2008-03-18 | 2013-05-28 | Bristol-Myers Squibb Company | Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof |
US8518895B2 (en) * | 2008-05-22 | 2013-08-27 | Bristol-Myers Squibb Company | Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same |
CA2725047A1 (en) * | 2008-05-22 | 2009-11-26 | Bristol-Myers Squibb Company | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
WO2009143021A1 (en) * | 2008-05-22 | 2009-11-26 | Bristol-Myers Squibb Company | Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
AU2009270936B2 (en) | 2008-07-15 | 2014-12-18 | Theracos, Inc. | Deuterated benzylbenzene derivatives and methods of use |
AU2014201286B2 (en) * | 2008-08-22 | 2015-07-02 | Theracosbio, Llc | Processes for the preparation of SGLT2 inhibitors |
ME02702B (me) * | 2008-08-22 | 2017-10-20 | Theracos Sub Llc | Postupci za pripremu inhibitora sgl t2 |
RS52236B (en) | 2008-08-28 | 2012-10-31 | Pfizer Inc. | DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA |
EP2395983B1 (en) | 2009-02-13 | 2020-04-08 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
ES2528404T3 (es) * | 2009-05-12 | 2015-02-10 | Bristol-Myers Squibb Company | Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos |
ES2446971T3 (es) * | 2009-05-12 | 2014-03-11 | Albany Molecular Research, Inc. | Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso |
ES2662072T3 (es) * | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
DK2496583T3 (en) | 2009-11-02 | 2015-02-02 | Pfizer | Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES |
LT2498758T (lt) | 2009-11-13 | 2018-11-26 | Astrazeneca Ab | Dvisluoksnės tabletės formuluotės |
PL2498759T3 (pl) | 2009-11-13 | 2019-03-29 | Astrazeneca Ab | Formulacje tabletek o natychmiastowym uwalnianiu |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US20140088027A1 (en) | 2010-03-30 | 2014-03-27 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
KR101931209B1 (ko) | 2010-05-11 | 2018-12-20 | 얀센 파마슈티카 엔.브이. | Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형 |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2012025857A1 (en) | 2010-08-23 | 2012-03-01 | Hetero Research Foundation | Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors |
KR20130137624A (ko) | 2010-09-03 | 2013-12-17 | 브리스톨-마이어스 스큅 컴퍼니 | 수용성 항산화제를 사용한 약물 제제 |
WO2012041898A1 (en) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
BR112013019026A2 (pt) | 2011-02-01 | 2016-10-04 | Astrazeneca Uk Ltd | formulações farmacêuticas incluindo um composto amina |
US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
AU2012241897C1 (en) | 2011-04-13 | 2017-05-11 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
MX2013014135A (es) | 2011-06-03 | 2014-01-23 | Boehringer Ingelheim Int | Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos. |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
BR112014010574A2 (pt) * | 2011-10-31 | 2017-05-02 | Scinopharm Taiwan Ltd | formas cristalinas e não cristalinas de inibidores sglt2 |
EP2597090A1 (en) * | 2011-11-28 | 2013-05-29 | Sandoz AG | Crystalline dapagliflozin hydrate |
TW201335176A (zh) | 2011-12-15 | 2013-09-01 | Nat Health Research Institutes | 新穎醣苷化合物 |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
CN103910769B (zh) | 2012-12-31 | 2018-10-02 | 上海璎黎药业有限公司 | 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用 |
CN103910719B (zh) * | 2012-12-31 | 2018-05-01 | 上海璎黎药业有限公司 | 葡萄糖衍生物与苯丙氨酸复合物、晶体、制备方法及应用 |
EP2968375B1 (en) | 2013-03-14 | 2019-06-12 | MSD International GmbH | Methods for preparing sglt2 inhibitors |
DK2981269T3 (da) | 2013-04-04 | 2023-10-23 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af stofskifteforstyrrelser hos hestedyr |
WO2014178040A1 (en) | 2013-04-29 | 2014-11-06 | Mapi Pharma Ltd. | Co-crystals of dapagliflozin |
US20160214953A1 (en) | 2013-09-23 | 2016-07-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of dapagliflozin |
US20160237054A1 (en) | 2013-09-27 | 2016-08-18 | Sun Pharmaceutical Industries Limited | Process for the purification of dapagliflozin |
CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
US20160280619A1 (en) | 2013-10-31 | 2016-09-29 | Sun Pharmaceutical Industries Limited | Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene |
KR20240017116A (ko) | 2013-12-17 | 2024-02-06 | 베링거잉겔하임베트메디카게엠베하 | 고양이과 동물에서 대사 장애의 치료 |
ES2951127T3 (es) | 2014-01-23 | 2023-10-18 | Boehringer Ingelheim Vetmedica Gmbh | Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales caninos |
CN104829572B (zh) * | 2014-02-10 | 2019-01-04 | 江苏豪森药业集团有限公司 | 达格列净新晶型及其制备方法 |
US20170056365A1 (en) | 2014-02-28 | 2017-03-02 | Sun Pharmaceutical Industries Limited | Dapagliflozin compositions |
IN2014CH01141A (ko) * | 2014-03-06 | 2015-09-11 | Msn Lab Private Ltd | |
US10688116B2 (en) | 2014-04-01 | 2020-06-23 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
EP3145934B1 (en) | 2014-05-19 | 2020-11-11 | Pfizer Inc | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
CN104031098A (zh) * | 2014-06-21 | 2014-09-10 | 李友香 | 降糖药物 |
CN104017031A (zh) * | 2014-06-21 | 2014-09-03 | 李友香 | 降血糖药物和组合物 |
US9676741B1 (en) | 2014-06-23 | 2017-06-13 | Sun Pharmaceutical Industries Limited | Co-crystal of dapagliflozin with citric acid |
US10555958B2 (en) | 2014-09-25 | 2020-02-11 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
JP2017528499A (ja) | 2014-09-25 | 2017-09-28 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | 肝臓の疾患を治療するためのオメガ3脂肪酸とsglt−2阻害薬との併用剤 |
CN104496952B (zh) * | 2014-11-28 | 2017-04-19 | 深圳翰宇药业股份有限公司 | 一种达格列净的合成方法 |
US20170342100A1 (en) * | 2014-12-03 | 2017-11-30 | Sun Pharmaceutical Industries Limited | Processes for the preparation of ertugliflozin |
CZ2015110A3 (cs) * | 2015-02-18 | 2016-08-31 | Zentiva, K.S. | Pevné formy empagliflozinu |
WO2016147197A1 (en) * | 2015-03-17 | 2016-09-22 | Harman Finochem Limited | A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form |
WO2016155578A1 (zh) * | 2015-03-27 | 2016-10-06 | 苏州晶云药物科技有限公司 | 达格列净的新晶型及其制备方法 |
WO2016161995A1 (en) | 2015-04-08 | 2016-10-13 | Zentiva, K.S. | Solid forms of amorphous dapagliflozin |
CN106146446B (zh) * | 2015-04-17 | 2019-11-08 | 杭州领业医药科技有限公司 | 达格列净半水合物及其晶型、其制备方法及药物组合物 |
US10556877B2 (en) | 2015-05-05 | 2020-02-11 | Glenmark Life Sciences Limited | Process for preparation of dapagliflozin |
SI3597189T1 (sl) | 2015-06-17 | 2022-08-31 | Otsuka America Pharmaceutical, Inc. | Kristalinične spojine |
WO2017042683A1 (en) * | 2015-09-07 | 2017-03-16 | Dr. Reddy's Laboratories Limited | Isolated intermediate of dapagliflozin, process for the preparation of isolated intermediate of dapagliflozin, process for the preparation of dapagliflozin |
US10428053B2 (en) | 2015-09-15 | 2019-10-01 | Laurus Labs Limited | Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
WO2017060925A1 (en) * | 2015-10-09 | 2017-04-13 | Harman Finochem Limited | Novel pipecolic acid co-crystals of dapagliflozin and process for the preparation thereof |
US9845303B2 (en) | 2015-10-19 | 2017-12-19 | Cadila Healthcare Limited | Process for the preparation of dapagliflozin |
US10555930B2 (en) * | 2015-11-27 | 2020-02-11 | North & South Brother Pharmacy Investment Company Limited | Complex of a glucopyranosyl derivative and preparation method and use thereof |
WO2017118945A1 (en) | 2016-01-08 | 2017-07-13 | Lupin Limited | Premix of dapagliflozin and process for the preparation thereof |
CN105503802A (zh) * | 2016-01-15 | 2016-04-20 | 中山大学 | 一种达格列净-柠檬酸共晶的制备方法 |
WO2017155841A1 (en) | 2016-03-11 | 2017-09-14 | Merck Sharp & Dohme Corp. | Methods of treating or reducing the risk of cardiovascular events and related diseases using sglt-2 inhibitors |
US20190110994A1 (en) | 2016-03-31 | 2019-04-18 | Lupin Limited | Pharmaceutical composition of dapagliflozin |
US10759772B2 (en) * | 2016-05-02 | 2020-09-01 | Aurobindo Pharma Ltd | Process for the preparation of DL-proline co-crystal of Dapagliflozin |
KR20190010578A (ko) | 2016-05-24 | 2019-01-30 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 새로운 다파글리플로진 결정형 및 그의 제조 방법 및 용도 |
WO2017203457A1 (en) * | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Solid state forms of empagliflozin |
WO2017203229A1 (en) | 2016-05-27 | 2017-11-30 | Cipla Limited | Dapagliflozin premixes |
EP3466940B1 (en) * | 2016-05-28 | 2021-11-17 | Ji Lin Hui Sheng Bio-Pharmaceutical Co., Ltd. | Crystal form of sodium-glucose cotransporter 2 inhibitor |
CN107445932A (zh) * | 2016-05-30 | 2017-12-08 | 上海医药工业研究院 | 达格列净共晶物的制备工艺 |
WO2017221211A1 (en) * | 2016-06-24 | 2017-12-28 | Biocon Limited | Process for the preparation of dapagliflozin and its solvate thereof |
CN107641139A (zh) | 2016-07-22 | 2018-01-30 | 江苏豪森药业集团有限公司 | 达格列净中间体的晶型及其制备方法 |
AU2017344882A1 (en) | 2016-10-19 | 2019-03-28 | Boehringer Ingelheim International Gmbh | Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof |
KR20180078762A (ko) * | 2016-12-30 | 2018-07-10 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물 |
WO2018124497A1 (ko) * | 2016-12-30 | 2018-07-05 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제 |
WO2018167589A1 (en) | 2017-03-16 | 2018-09-20 | Inventia Healthcare Private Limited | Pharmaceutical composition comprising dapagliflozin |
TWI797133B (zh) | 2017-06-09 | 2023-04-01 | 丹麥商諾佛 儂迪克股份有限公司 | 用於經口投予的固體組成物 |
CN107488156B (zh) * | 2017-09-04 | 2020-05-26 | 上海现代制药股份有限公司 | 一种无定型葡萄糖醇的合成方法 |
CN108516966A (zh) * | 2017-10-19 | 2018-09-11 | 浙江海正药业股份有限公司 | 达格列净的晶型及其制备方法和用途 |
KR20190115948A (ko) | 2018-04-04 | 2019-10-14 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물 |
WO2019201752A1 (en) | 2018-04-17 | 2019-10-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
KR102204439B1 (ko) | 2018-05-14 | 2021-01-18 | 에이치케이이노엔 주식회사 | Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물 |
KR20210034039A (ko) * | 2018-07-19 | 2021-03-29 | 아스트라제네카 아베 | 다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물 |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
WO2020068661A1 (en) * | 2018-09-26 | 2020-04-02 | Lexicon Pharmaceuticals, Inc. | Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis |
BR112021006002A2 (pt) | 2018-10-01 | 2021-06-29 | Astrazeneca Ab | composições para a redução de ácido úrico sérico |
CN109705075B (zh) * | 2018-12-13 | 2022-12-23 | 苏中药业集团股份有限公司 | 一种达格列净的纯化方法 |
CN109705076B (zh) * | 2019-01-21 | 2023-03-24 | 苏中药业集团股份有限公司 | 一种达格列净晶型、制备方法及其用途 |
CN111559997A (zh) * | 2019-02-13 | 2020-08-21 | 罗欣药业(上海)有限公司 | 一种达格列净新晶型及其制备方法 |
CN111689936A (zh) * | 2019-03-15 | 2020-09-22 | 罗欣药业(上海)有限公司 | 达格列净新晶型及其制备方法 |
US20220395559A1 (en) | 2019-11-07 | 2022-12-15 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
MX2019014226A (es) * | 2019-11-27 | 2022-09-23 | Alparis Sa De Cv | Nuevas fases sólidas de dapagliflozina. |
US11759474B2 (en) | 2019-11-28 | 2023-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors in the drying-off of non-human mammals |
AU2020413580A1 (en) * | 2019-12-24 | 2022-06-30 | Hanmi Pharm. Co., Ltd. | Complex formulation comprising sitagliptin and dapagliflozin, and preparation method therefor |
CA3167531A1 (en) | 2020-02-17 | 2021-08-26 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
WO2021165316A1 (en) | 2020-02-21 | 2021-08-26 | Zakłady Farmaceutyczne POLPHARMA S.A. | Pharmaceutical composition comprising dapagliflozin |
WO2021176096A1 (en) | 2020-03-05 | 2021-09-10 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising sglt2 inhibitor |
CN115916197A (zh) | 2020-04-22 | 2023-04-04 | 拜耳公司 | 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合 |
WO2021219691A1 (en) | 2020-04-29 | 2021-11-04 | Astrazeneca Ab | Dapagliflozin and ambrisentan for the prevention and treatment of covid-19 |
KR20220007446A (ko) * | 2020-07-10 | 2022-01-18 | 한미약품 주식회사 | 시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법 |
US20220023252A1 (en) | 2020-07-27 | 2022-01-27 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
WO2022067724A1 (zh) | 2020-09-30 | 2022-04-07 | 北京睿创康泰医药研究院有限公司 | 一种sglt-2抑制剂·肌氨酸共晶体及其制备方法和应用 |
WO2023006745A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
CN117715640A (zh) | 2021-07-28 | 2024-03-15 | 勃林格殷格翰动物保健有限公司 | Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物,特别是犬科动物中预防和/或治疗心脏疾病的用途 |
KR20240040106A (ko) | 2021-07-28 | 2024-03-27 | 베링거잉겔하임베트메디카게엠베하 | 비-사람 포유류에서 신장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도 |
CN114394993B (zh) * | 2021-11-11 | 2023-11-10 | 苏州正济药业有限公司 | 一种达格列净中间体的制备方法 |
CN114213399A (zh) * | 2021-12-20 | 2022-03-22 | 上海启讯医药科技有限公司 | 一种卡格列净丙酮水合物及其制备方法和用途 |
WO2023129595A1 (en) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2023227492A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
WO2024033519A1 (en) | 2022-08-12 | 2024-02-15 | Astrazeneca Ab | Combination therapies for treatment of cirrhosis with portal hypertension |
WO2024047574A1 (en) | 2022-09-01 | 2024-03-07 | Astrazeneca Ab | Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases |
WO2024062310A1 (en) * | 2022-09-22 | 2024-03-28 | Savoi Guilherme | Co-crystals derived from empagliflozin and dapagliflozin with l-proline |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5612114B2 (ko) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
KR910003427B1 (ko) | 1984-12-04 | 1991-05-31 | 산도즈 파마슈티칼스 코포레이션 | 메발로노락톤의 인덴동족체 및 이들의 유도체의 제법 |
US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
HUT48208A (en) | 1985-10-25 | 1989-05-29 | Sandoz Ag | Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds |
FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
SE503210C2 (sv) | 1987-05-22 | 1996-04-22 | Squibb & Sons Inc | Fosforhaltiga HMG- CoA- Reduktasinhibitoret, nya intermediat och sätt |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
US5470845A (en) | 1992-10-28 | 1995-11-28 | Bristol-Myers Squibb Company | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
CA2150372C (en) | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
US5340583A (en) | 1993-05-06 | 1994-08-23 | Allergan, Inc. | Antimicrobial lenses and lens care systems |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
DE69636677D1 (de) | 1995-12-13 | 2006-12-14 | Univ California | Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
CA2819705C (en) | 1998-02-02 | 2014-07-08 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
AU3034299A (en) | 1998-03-09 | 1999-09-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
GB9807354D0 (en) * | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
SK18822000A3 (sk) | 1998-07-06 | 2001-12-03 | Bristol-Myers Squibb Company | Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora |
US6069238A (en) | 1998-09-30 | 2000-05-30 | Eli Lilly And Company | Spirocyclic C-glycosides |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
TW200528436A (en) | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
KR20020014570A (ko) * | 2000-08-18 | 2002-02-25 | 김충섭 | 고체분산화시킨 무정형 이프리플라본의 제조방법 |
US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
AU2002254567B2 (en) | 2001-04-11 | 2007-10-11 | Bristol-Myers Squibb Company | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
MXPA03010028A (es) * | 2001-05-22 | 2004-02-12 | Pfizer Prod Inc | Formas cristalinas de azitromicina. |
EP1572892A4 (en) | 2001-10-18 | 2007-08-22 | Bristol Myers Squibb Co | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS |
WO2004060347A2 (en) | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
WO2004061433A1 (en) * | 2002-12-30 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
EP1511490A4 (en) * | 2002-05-31 | 2009-03-11 | Transform Pharmaceuticals Inc | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS |
CA2512389A1 (en) * | 2003-01-03 | 2004-07-29 | Bristol-Myers Squibb Company | Methods of producing c-aryl glucoside sglt2 inhibitors |
WO2004076470A2 (en) | 2003-02-27 | 2004-09-10 | Bristol-Myers Squibb Company | A non-cryogenic process for forming glycosides |
EP1980560B1 (en) * | 2003-03-14 | 2011-05-25 | Astellas Pharma Inc. | C-glycoside derivatives for the treatment of diabetes |
EP1595880A1 (en) * | 2004-05-13 | 2005-11-16 | Speedel Pharma AG | Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists |
MXPA06014478A (es) * | 2004-06-11 | 2007-03-21 | Japan Tobacco Inc | Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer. |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
CN104829572B (zh) | 2014-02-10 | 2019-01-04 | 江苏豪森药业集团有限公司 | 达格列净新晶型及其制备方法 |
-
2007
- 2007-06-20 US US11/765,481 patent/US7919598B2/en active Active
- 2007-06-21 MX MX2016006205A patent/MX367155B/es unknown
- 2007-06-21 CN CN201310052369.2A patent/CN103145773B/zh active Active
- 2007-06-21 EP EP07784499.1A patent/EP2069374B2/en active Active
- 2007-06-21 SG SG2011047727A patent/SG172741A1/en unknown
- 2007-06-21 EA EA201490902A patent/EA028259B1/ru not_active IP Right Cessation
- 2007-06-21 PL PL07784499T patent/PL2069374T5/pl unknown
- 2007-06-21 NZ NZ589195A patent/NZ589195A/en unknown
- 2007-06-21 BR BR122017015106A patent/BR122017015106B8/pt active IP Right Grant
- 2007-06-21 DK DK07784499.1T patent/DK2069374T4/da active
- 2007-06-21 BR BRPI0713544A patent/BRPI0713544B8/pt active IP Right Grant
- 2007-06-21 ES ES15181545.3T patent/ES2659862T3/es active Active
- 2007-06-21 BR BR122017021516A patent/BR122017021516B8/pt active IP Right Grant
- 2007-06-21 EP EP15181545.3A patent/EP3045466B1/en active Active
- 2007-06-21 KR KR1020087031643A patent/KR101493102B1/ko active IP Right Review Request
- 2007-06-21 MX MX2008015377A patent/MX2008015377A/es active IP Right Grant
- 2007-06-21 NO NO20085169A patent/NO346828B1/no unknown
- 2007-06-21 EA EA201171333A patent/EA020428B1/ru not_active IP Right Cessation
- 2007-06-21 PT PT77844991T patent/PT2069374E/pt unknown
- 2007-06-21 CN CN200780024135XA patent/CN101479287B/zh active Active
- 2007-06-21 CA CA2653344A patent/CA2653344C/en active Active
- 2007-06-21 UA UAA200900606A patent/UA96765C2/uk unknown
- 2007-06-21 EA EA200900066A patent/EA018229B1/ru not_active IP Right Cessation
- 2007-06-21 AU AU2007265246A patent/AU2007265246B2/en active Active
- 2007-06-21 JP JP2009518468A patent/JP5313889B2/ja active Active
- 2007-06-21 MY MYPI20085336A patent/MY148566A/en unknown
- 2007-06-21 ES ES07784499T patent/ES2521665T5/es active Active
- 2007-06-21 EP EP17203302.9A patent/EP3363807B1/en active Active
- 2007-06-21 MY MYPI2014001983A patent/MY173930A/en unknown
- 2007-06-21 NZ NZ589190A patent/NZ589190A/en unknown
- 2007-06-21 MX MX2011009646A patent/MX339143B/es unknown
- 2007-06-21 ES ES17203302T patent/ES2769130T3/es active Active
- 2007-06-21 NZ NZ589202A patent/NZ589202A/en unknown
- 2007-06-21 RS RS20140570A patent/RS53638B2/sr unknown
- 2007-06-21 CA CA2985797A patent/CA2985797A1/en not_active Abandoned
- 2007-06-21 SI SI200731535T patent/SI2069374T2/sl unknown
- 2007-06-21 CA CA2924318A patent/CA2924318C/en active Active
- 2007-06-21 WO PCT/US2007/071749 patent/WO2008002824A1/en active Application Filing
- 2007-06-21 EP EP12152907A patent/EP2457918A3/en not_active Withdrawn
- 2007-06-21 NZ NZ574346A patent/NZ574346A/en unknown
- 2007-06-21 SG SG10201402181SA patent/SG10201402181SA/en unknown
- 2007-06-21 EA EA201791254A patent/EA035999B1/ru not_active IP Right Cessation
- 2007-06-28 TW TW102137967A patent/TWI466876B/zh not_active IP Right Cessation
- 2007-06-28 CL CL2007001915A patent/CL2007001915A1/es unknown
- 2007-06-28 TW TW096123519A patent/TWI421245B/zh not_active IP Right Cessation
- 2007-06-28 TW TW103140880A patent/TWI519528B/zh not_active IP Right Cessation
- 2007-06-28 TW TW104129264A patent/TW201546054A/zh unknown
- 2007-06-28 AR ARP070102896A patent/AR061730A1/es not_active Application Discontinuation
- 2007-07-02 PE PE2007000845A patent/PE20080349A1/es not_active Application Discontinuation
- 2007-07-02 PE PE2011001791A patent/PE20120776A1/es not_active Application Discontinuation
-
2008
- 2008-11-10 ZA ZA2008/10475A patent/ZA200810475B/en unknown
- 2008-12-11 IL IL195882A patent/IL195882A/en active IP Right Grant
- 2008-12-24 CO CO08136743A patent/CO6160299A2/es unknown
-
2009
- 2009-07-16 HK HK09106471.6A patent/HK1127359A1/xx active IP Right Maintenance
-
2011
- 2011-03-16 US US13/049,712 patent/US8501698B2/en active Active
- 2011-07-19 IL IL214180A patent/IL214180A/en active IP Right Grant
- 2011-07-19 IL IL214181A patent/IL214181A/en active IP Right Grant
- 2011-07-19 IL IL214182A patent/IL214182A/en active IP Right Grant
-
2012
- 2012-01-26 PH PH12012500168A patent/PH12012500168A1/en unknown
-
2013
- 2013-05-14 JP JP2013102220A patent/JP5666651B2/ja active Active
- 2013-07-10 US US13/938,763 patent/US9453039B2/en active Active
-
2014
- 2014-10-21 HR HRP20141007TT patent/HRP20141007T4/hr unknown
- 2014-10-29 CY CY20141100887T patent/CY1115738T1/el unknown
- 2014-12-10 JP JP2014250141A patent/JP5937187B2/ja active Active
-
2016
- 2016-05-11 JP JP2016095472A patent/JP2016172758A/ja active Pending
- 2016-05-17 IL IL245688A patent/IL245688A0/en unknown
-
2017
- 2017-07-07 JP JP2017133952A patent/JP2017222681A/ja active Pending
-
2018
- 2018-12-18 JP JP2018236514A patent/JP2019059779A/ja active Pending
-
2022
- 2022-11-17 NO NO20221233A patent/NO347770B1/no unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016018024A1 (ko) * | 2014-07-28 | 2016-02-04 | 한미정밀화학주식회사 | 다파글리프로진을 포함하는 결정질 복합체 및 이의 제조방법 |
WO2017099496A1 (ko) * | 2015-12-11 | 2017-06-15 | 동아에스티 주식회사 | 다파글리플로진의 신규 용매화물 및 이의 제조방법 |
KR20170069943A (ko) * | 2015-12-11 | 2017-06-21 | 동아에스티 주식회사 | 다파글리플로진의 신규 용매화물 및 이의 제조방법 |
WO2018097570A3 (ko) * | 2016-11-24 | 2018-08-09 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 |
KR20190038283A (ko) * | 2017-09-29 | 2019-04-08 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제 |
WO2019066359A3 (ko) * | 2017-09-29 | 2019-05-16 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5937187B2 (ja) | 糖尿病の治療用sglt2阻害剤としてのアミノ酸を有する(1s)−1,5−アンヒドロ−1−c−(3−((フェニル)メチル)フェニル)−d−グルシトール誘導体の結晶性溶媒和物および複合体 | |
US7943656B2 (en) | Crystal forms of saxagliptin and processes for preparing same | |
JP2010528023A (ja) | Sglt2阻害剤の結晶構造およびその製造方法 | |
EA042128B1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
N231 | Notification of change of applicant | ||
E701 | Decision to grant or registration of patent right | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J501 | Disposition of invalidation of trial | ||
J501 | Disposition of invalidation of trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20151014 Effective date: 20160323 Free format text: TRIAL NUMBER: 2015100004907; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20151014 Effective date: 20160323 |
|
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
FPAY | Annual fee payment |
Payment date: 20180118 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190116 Year of fee payment: 5 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100002343; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170725 Effective date: 20190123 Free format text: TRIAL NUMBER: 2017100002661; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170823 Effective date: 20190123 Free format text: TRIAL NUMBER: 2017100002633; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170821 Effective date: 20190123 Free format text: TRIAL NUMBER: 2017100002662; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170823 Effective date: 20190123 Free format text: TRIAL NUMBER: 2017100002423; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170731 Effective date: 20190123 Free format text: TRIAL NUMBER: 2017100002173; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170710 Effective date: 20190123 Free format text: TRIAL NUMBER: 2017100002432; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170801 Effective date: 20190123 Free format text: TRIAL NUMBER: 2017100004078; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20171229 Effective date: 20190123 |
|
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015100001475; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001874; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001765; TRIAL DECISION FOR INVALIDATION REQUESTED 20150402 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001929; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001176; TRIAL DECISION FOR INVALIDATION REQUESTED 20150320 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001470; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001178; TRIAL DECISION FOR INVALIDATION REQUESTED 20150320 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001478; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001875; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001642; TRIAL DECISION FOR INVALIDATION REQUESTED 20150328 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001767; TRIAL DECISION FOR INVALIDATION REQUESTED 20150402 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001890; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100001174; TRIAL DECISION FOR INVALIDATION REQUESTED 20150320 Effective date: 20190620 Free format text: TRIAL NUMBER: 2015100002020; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403 Effective date: 20190620 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019100001163; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20190412 Effective date: 20190624 |
|
G170 | Re-publication after modification of scope of protection [patent] |